文
论文分享
演练场
杂货铺
论文推荐
字
编辑器下载
登录
注册
Thomas Cheung Yau
发表
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
H. Harputluoglu, S. Yoon, H. Marusawa, 2023, The Lancet.
Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.
M. Kudo, A. El-Khoueiry, B. Sangro, 2018 .